Xeris Biopharma Holdings Future Growth
Future criteria checks 4/6
Xeris Biopharma Holdings is forecast to grow earnings and revenue by 70.2% and 17.2% per annum respectively while EPS is expected to grow by 70.6% per annum.
Key information
70.2%
Earnings growth rate
70.6%
EPS growth rate
| Pharmaceuticals earnings growth | 24.0% |
| Revenue growth rate | 17.2% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 26 Nov 2024 |
Recent future growth updates
Recent updates
Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive
Oct 25Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Could Be Riskier Than It Looks
Sep 07
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Rockets 30% But Many Are Still Ignoring The Company
Jun 04Xeris Biopharma: Checking-In On One Of My 'Top Ideas'
Mar 30Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results
Mar 09Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 26% But Its Business Is Yet to Catch Up
Mar 06Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Fly 32% But Investors Aren't Buying For Growth
Jan 05Xeris Pharmaceuticals Q2 2022 Earnings Preview
Aug 09Xeris amends commercial terms for hypoglycemia therapy as partner inks buyout deal
Aug 01Xeris Biopharma: Q1 Earnings Reveal Path To Breakeven
May 21Xeris Continues To Execute And Build Long-Term Value Potential
Feb 22Xeris Biopharma: Market Is Snubbing The Strongbridge Acquisition
Dec 20Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 283 | 7 | N/A | 54 | 5 |
| 12/31/2025 | 237 | -35 | -18 | -2 | 6 |
| 12/31/2024 | 200 | -60 | -40 | -31 | 6 |
| 9/30/2024 | 187 | -63 | -32 | -31 | N/A |
| 6/30/2024 | 181 | -60 | -39 | -38 | N/A |
| 3/31/2024 | 171 | -64 | -43 | -41 | N/A |
| 12/31/2023 | 164 | -62 | -49 | -47 | N/A |
| 9/30/2023 | 153 | -62 | -73 | -71 | N/A |
| 6/30/2023 | 134 | -71 | -76 | -74 | N/A |
| 3/31/2023 | 121 | -78 | -81 | -81 | N/A |
| 12/31/2022 | 110 | -95 | -103 | -103 | N/A |
| 9/30/2022 | 99 | -133 | -116 | -116 | N/A |
| 6/30/2022 | 80 | -137 | -121 | -121 | N/A |
| 3/31/2022 | 63 | -138 | -121 | -120 | N/A |
| 12/31/2021 | 50 | -123 | -97 | -96 | N/A |
| 9/30/2021 | 35 | -94 | -79 | -77 | N/A |
| 6/30/2021 | 34 | -84 | -73 | -72 | N/A |
| 3/31/2021 | 27 | -80 | -76 | -76 | N/A |
| 12/31/2020 | 20 | -91 | -81 | -81 | N/A |
| 9/30/2020 | 15 | -102 | -100 | -99 | N/A |
| 6/30/2020 | 6 | -119 | -114 | -113 | N/A |
| 3/31/2020 | 4 | -129 | -113 | -112 | N/A |
| 12/31/2019 | 3 | -126 | -105 | -104 | N/A |
| 9/30/2019 | 2 | -113 | -94 | -93 | N/A |
| 6/30/2019 | 2 | -95 | -80 | -78 | N/A |
| 3/31/2019 | 2 | -73 | -71 | -70 | N/A |
| 12/31/2018 | 2 | -60 | -58 | -56 | N/A |
| 9/30/2018 | 2 | -49 | -49 | -47 | N/A |
| 6/30/2018 | 2 | -42 | N/A | -37 | N/A |
| 3/31/2018 | 1 | -34 | N/A | -29 | N/A |
| 12/31/2017 | 2 | -27 | N/A | -25 | N/A |
| 12/31/2016 | 1 | -13 | N/A | -16 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XERS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: XERS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: XERS is expected to become profitable in the next 3 years.
Revenue vs Market: XERS's revenue (17.2% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: XERS's revenue (17.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if XERS's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 05:49 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Xeris Biopharma Holdings, Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |
| Robin Garner Kalley | Craig-Hallum Capital Group LLC |
| Oren Livnat | H.C. Wainwright & Co. |